Latest Covance Inc (CVD) Headlines 17.4% Return
Post# of 13
Posted On: 03/14/2014 1:19:29 PM
Latest Covance Inc (CVD) Headlines
17.4% Return Seen to Date on SmarTrend Covance Call (CVD)
Comtex SmarTrend(R) - 2 hrs 28 mins ago
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on December 9th, 2013 at $87.45. In approximately 3 months, Covance has returned 17.37% as of today's recent price of $102.64.
Pharmacovigilance Market Research Report - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Thu Mar 13, 4:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rs95v7/pharmacovigilance) has announced the addition of the "Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. A rising tide of regulatory expectations, tougher inspection regime and instant need of patient reporting has provided the much needed impetus for the growth of the pharmacovigilance market. An upsurge in number of acute and chronic diseases has consequently led to a rise in number of drug consumption, which has also elicited a growth in the number of adverse drug events and drug toxicity cases. Moreover, several high-profile safety issues, regulatory warnings, large volume of events to be reviewed along with negative media coverage have compelled the pharmaceutical players to take support of various outsourcing services. There are two major outsourcing services opted by these pharmaceutical players i.e. traditional CROs and BPOs. These outsourcing services not only provide cost savings but also helps in bringing process efficiency. Pharmaceutical companies are now forming long term partnership with the CROs and BPOs to share the costs involved in PV process right from drug discovery to post marketing approvals. In addition, PV requires skilled resources with excellent language skills and strong knowledge pertaining to case reporting. The research report on pharmacovigilance provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of pharmacovigilance market on the bases of clinical trials phases i.e. Phase I to III and post marketing surveillance (PMS). We have also mapped the trend for preference of the pharmaceutical players for in-house and outsourcing in our chapter by type of service. The global pharmacovigilance market has been segmented based on all the above mentioned parameters and market size estimates and forecasts for the period of 2011 to 2019 have been provided for each of the segments, in term of USD million, considering 2012 as the base year for calculations and 2011 representing as the historical year. The CAGR (%) of each market segment for the forecast period 2013 to 2019 has also been provided along with market size estimations. The report exclusively studies the aforementioned segments with respect to geography. Under geographic section we have covered four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (ROW). The market overview section gives a detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global pharmacovigilance market. The section also covers opportunities and market attractiveness analysis of the geographical regions. The report concludes with the competitive landscape and company profiles of major market players. These market players have been profiled on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Key Topics Covered: Introduction Executive Summary Global Pharmacovigilance Market Dynamics Global Pharmacovigilance Market, by Clinical Trial Phases Global Pharmacovigilance Market, By Type of Methods Global Pharmacovigilance Market, by Type of Service Providers Global Pharmacovigilance Market, by Geography Global Pharmacovigilance Market Share Analysis Recommendations Company Profiles List of Figures List of Tables Companies Mentioned - Accenture, Plc - Bristol-Myers Squibb - Clinquest Group B.V. - Cognizant Technology Solutions - Covance, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline (GSK) - iGATE Corporation - iMEDGlobal Corporation - inVentiv Health Inc. - ICON, Plc - Infosys - Johnson and Johnson - Novartis International AG - OptumInsight, Inc. - PRA International, Inc. - Parexel International Corporation - Pfizer, Inc. - Pharmaceutical Product Development, Inc. (PPD, Inc.) - Quantum Solutions India - Quintiles Transnational Corporation - Sanofi Aventis - Synowledge LLC - United BioSource Corporation - Wipro Limited For more information visit http://www.researchandmarkets.com/research/rs...ovigilance About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Mice Model Market 2014 - Forecasts to 2018: Inbred, Knockout & Conditioned
M2 - Wed Mar 12, 10:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lmb6vx/mice_model_market) has announced the addition of the "Mice Model Market 2014 - Forecasts to 2018: Inbred, Knockout & Conditioned" report to their offering. The global market (models and services) is valued at $1,115.2 million in 2013 and is expected to reach $1,819.9 million by 2018, growing at a CAGR of 10.3% from 2013 to 2018. Over the years, the use of mice models has increased rapidly. Mice have become the animals of choice for preclinical research in academic institutions as well as in pharmaceutical and biotechnology industries. The market has seen many innovations in the last few years, as companies have introduced new models for studying diseases like cancer and AIDS. This report categorizes the market into two broad segments, namely, mice models and services. By type, the market comprises of inbred, outbred, knockout, conditioned/surgically modified, hybrid/congenic, and spontaneous mutant mice. The inbred mice segment holds the largest share of 58% of the mice model market in 2013. This high share of inbred mice is attributed to their ability to reproduce the same results in different laboratories over a period of time. The market for mice model services is segmented into breeding, cryopreservation, quarantine, rederivation, genetic testing, model in-licensing, and other services (surgical and line rescue). The breeding services market holds the largest share of the services market and is expected to grow at the highest CAGR of 15% from 2013 to 2018, to reach $521 million by 2018. The mice care products market is categorized into cages, bedding, feed, and others. The caging market accounts for the largest share of the mice care products market, growing at a CAGR of 2.8% from 2013 to 2018 to reach $67.1 million in 2018. High investments and grants, which are leading to rising innovations in mice models, is a key factor that is likely to drive the growth of this market. In addition, the increase in the number of R&D activities in pharmaceutical industries, which are the prime users of mice models, is also responsible for driving this market. Furthermore, the high genetic similarity between mice and humans is another factor that is driving the use of mice models, globally. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Dynamics 4 Market Share Analysis, By Key Players 5 Mice Model Market Size 6 Geographic Analysis 7 Competitive Landscape 8 Company Profiles 9 Preclinical Pipeline 10 Industry Speaks 11 Cost Assessment and Mouse Model Outlicensing/Buyer Companies Assessment Companies Mentioned - Ablexis, LLC - Charles River Laboratories, Inc. - Covance, Inc. - Crescendo Biologics, - Deltagen, Inc. - Genoway Sa - Harbour Antibodies Bv - Harlan Laboratories, Inc. - Immunogenes Ag - Ingenious Targeting Laboratory - Lexicon Pharmaceuticals, Inc. - Mirimus, Inc. - Sage Labs - Taconic Farms, Inc. - The Jackson Laboratory - Transgenic, Inc. For more information visit http://www.researchandmarkets.com/research/lm...del_market
Global Life Sciences BPO Market Market Forecasts & Opportunities, 2019
M2 - Mon Mar 10, 9:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gh67xx/life_sciences_bpo) has announced the addition of the "Global Life Sciences BPO Market Market Forecasts & Opportunities, 2019" report to their offering. The life sciences BPO market comprises services offered by Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) to the biotech pharmaceutical companies. A rise in demand for low cost drugs, patent expirations and uncertain economic conditions have compelled the pharmaceutical players to take support of various outsourcing services. This support has facilitated pharma players to streamline their value chain and focus more on its core strategies. Pharmaceutical companies are now forming long term partnership with the CROs and CMOs to share the costs involved in drug discovery to post marketing approvals. Moreover, they are also leveraging CROs and CMOs expertise such as use of novel technologies, trained staff and previous experiences for effective outcomes. The research report on life sciences BPO provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of life sciences BPO on the basis of different CRO and CMO services. The CRO services comprises clinical data management, monitoring, medical writing, regulatory services, pharmacovigilance, bio-statistics, drug discovery and pre-clinical tests. The CMO services include API manufacturing, Finished Dosage Formulation development and manufacturing and Packaging. The global life sciences BPO market has been segmented based on all the above- mentioned parameters and market size estimates and forecasts for the period of 2011 to 2019 have been provided for each of the segments, in terms of USD million, considering 2012 as the base year for calculations and 2011 representing as the historical year. The market overview section gives a detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global life sciences BPO market.The section also covers opportunities, market attractiveness analysis and Porter's Five Forces analysis for the market participants. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Life Sciences BPO Market Dynamics Chapter 4 Global Life Sciences BPO Market, by Segments Chapter 5 Global Life Sciences BPO Market, by Geography Chapter 6 Global Life Sciences BPO Market Share Analysis Chapter 7 Recommendations Chapter 8 Company Profiles - Accenture, Plc - Boehringer Ingelheim GmbH - Catalent Pharma Solutions, Inc. - Charles River Laboratories International, Inc. (CRL) - Cognizant Technology Solutions - Covance, Inc. - DSM - Fareva - ICON, Plc - Infosys - International Business Machines Corporation - Lonza Group - Pharmaceutical Product Development, Inc. (PPD, Inc.) - Parexel International Corporation - Patheon, Inc. - Piramal Healthcare - PRA International, Inc. - Quintiles Transnational Corporation - Wipro Limited For more information visit http://www.researchandmarkets.com/research/gh...iences_bpo
Covance Up 18.8% Since SmarTrend Uptrend Call (CVD)
Comtex SmarTrend(R) - Fri Mar 07, 9:21AM CST
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on December 9th, 2013 at $87.45. In approximately 3 months, Covance has returned 18.78% as of today's recent price of $103.87.
Coverage on Covance Initiated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 2:20PM CST
On Mar 06, 2014, we initiated coverage on Covance.
Favorable Court Judgments, Stock Price Updates, and Upcoming Investors Conferences - Analyst Notes on Salix, Cerner, Hologic, Covance, and Synta
PR Newswire - Thu Mar 06, 8:20AM CST
Today, Analysts Review released its analysts' notes regarding Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Cerner Corporation (NASDAQ: CENR), Hologic Inc. (NASDAQ: HOLX), Covance Inc. (NYSE: CVD), and Synta Pharmaceuticals Corp. (NASDAQ: SNTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
MedAssets Beats on Q4 Earnings, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 9:45AM CST
Following the favorable earnings announcement, shares of MedAssets rose 10.8% till the last closing date
The US Clinical Research Market Outlook to 2017: Value Chain, Market Size and Segmentation by Major Therapeutic Areas
M2 - Mon Mar 03, 11:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/vt6rd9/the_us_clinical) has announced the addition of the "The US Clinical Research Market Outlook to 2017 - Led by Aging Population and Rise of Chronic Diseases" report to their offering. The report titled The US Clinical Research Market Outlook to 2017 - Led by Aging Population and Rise of Chronic Diseases' provides a comprehensive analysis of the various aspects such as market size, segmentation, trends and developments and future projections of the therapeutic areas of Oncology, Central Nervous System Disorders, Cardiovascular Diseases, Infectious Diseases and Metabolic disorders as key segments of the market. The report also provides a detailed explanation of the various macro and industry factors which are driving the growth of clinical research in the US. - The market size of The US Clinical Research Market on the basis of revenue earned by the contract research organizations in the country. - The market segmentation of The US Clinical Research Market on the basis of therapeutic areas of Oncology, Central Nervous System Disorders, Cardiovascular Diseases, Infectious Diseases and Metabolic Disorders. - The market segmentation of Oncology on the basis revenue generated in key medical conditions of Oncology which include Breast Cancer, Lung Cancer, Leukemia, Prostate Cancer, Non Small Cell Lung Cancer and other kinds of cancers. - The market size of Breast Cancer, Lung Cancer, Leukemia, Prostate Cancer, Non Small Cell Lung Cancer and other kinds of cancers on the basis of revenue generated from clinical research in these areas. - Future Outlook and Projections of Oncology and its key medical conditions. - The market size of Central Nervous System Disorders on the basis of revenue. - The market segmentation of Central Nervous System Disorders on the basis revenue generated in its key medical conditions which comprise of Strokes, Schizophrenia, Alzheimer, Multiple Sclerosis, Epilepsy and other Central Nervous System Disorders. - Future Outlook and Projections of Central Nervous System Disorders and its key medical conditions. - The market size of Cardiovascular Diseases on the basis of revenue. - The market segmentation of Cardiovascular Diseases on the basis revenue generated in its key medical conditions which comprise of Coronary Artery Disease and Heart Failures. - Future Outlook and Projections of Cardiovascular Diseases and its key medical conditions. - The market size of Infectious Diseases on the basis of revenue. - The market segmentation of Infectious Diseases on the basis revenue generated in its key medical conditions which comprise of HIV/AIDS and Hepatitis (A, B and C) - Future Outlook and Projections of Infectious Diseases and its key medical conditions. - The market size of metabolic disorders on the basis of revenue. - The market segmentation of Metabolic Disorders on the basis revenue generated in its key medical conditions which comprise of Diabetes and other metabolic disorders. - Future Outlook and Projections of Metabolic Disorders and its key medical conditions. - The market size of other therapeutic areas. - Future Outlook and Projections of other therapeutic areas. - The Future Outlook and Projections of The US Clinical Research Market on the basis of revenue. Companies Mentioned: - Albany Molecular Research inc - Charles River - Covance inc - ICON - INC Research - Inventiv Health Care - PRA International - Parexel - Pharmaceutical Product Development (PPD) - Quintiles inc For more information visit http://www.researchandmarkets.com/research/vt...s_clinical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Covance To Present At The Raymond James 35th Annual Institutional Investors Conference
PR Newswire - Mon Mar 03, 9:29AM CST
Covance Inc. (NYSE: CVD) today announced that it will present at the Raymond James 35th Annual Institutional Investors Conference on Monday, March 3, 2014 at 4:35 p.m. (ET). Investors may access a live webcast of the presentation and related slides at www.covance.com. In order to register and download any necessary software, please log on 10 minutes early.
Covance Shares Up 18.5% Since SmarTrend's Buy Recommendation (CVD)
Comtex SmarTrend(R) - Thu Feb 27, 5:02PM CST
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on December 9th, 2013 at $87.45. In approximately 3 months, Covance has returned 18.55% as of today's recent price of $103.67.
Insider Trading Alert - MXIM, CVD And NOC Traded By Insiders
at The Street - Thu Feb 27, 9:30AM CST
Stocks with insider trader activity include MXIM, CVD and NOC
Surging Rank, Surging Stock: Why BioTelemetry (BEAT) Is a Winner? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 7:38AM CST
BioTelemetry (BEAT) sees rank surges as well as price appreciation over the past few weeks, gaining over 36% in the past month.
Covance To Present At The Citi 2014 Global Healthcare Conference
PR Newswire - Mon Feb 24, 5:00PM CST
Covance Inc. (NYSE: CVD) today announced that it will present at the Citi 2014 Global Healthcare Conference on Wednesday, February 26, 2014 at 1:50 p.m. (ET). Investors may access a live webcast of the presentation and related slides at www.covance.com. In order to register and download any necessary software, please log on 10 minutes early.
Omnicare Earnings Rise but Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 11:30AM CST
For full year 2013, OCR's adjusted net earnings per share grew 9.9% to $3.43 from $3.12 a year ago, also lagging the Zacks Consensus Estimate of $3.61.
Shares of CVD Up 17.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Feb 20, 11:10AM CST
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on December 9th, 2013 at $87.45. In approximately 2 months, Covance has returned 17.72% as of today's recent price of $102.95.
Omnicare (OCR) Falls: Stock Goes Down 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 7:37AM CST
Omnicare Inc. (OCR) saw a big move last session. This stock, trading at a volatile range of $60.68–$64.54 in the past one-month time frame, showed a sharp decline yesterday at $60.98.
Why Quintiles Transnational (Q) Has A Bright Short-Term Future? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 7:30AM CST
Quintiles Transnational has seen its Zacks Rank move up from Buy to Strong Buy over the past four weeks
Why Covance (CVD) Could Be an Impressive Growth Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 7:32AM CST
Covance is well-positioned for future earnings growth and could be a strong growth stock contender
Quintiles Transnational Holdings (Q) Jumps: Stock Rises 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 7:57AM CST
Quintiles Transnational Holdings Inc. (Q) was a big mover last session, as the company saw its shares rise over 5% on the day.
17.4% Return Seen to Date on SmarTrend Covance Call (CVD)
Comtex SmarTrend(R) - 2 hrs 28 mins ago
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on December 9th, 2013 at $87.45. In approximately 3 months, Covance has returned 17.37% as of today's recent price of $102.64.
Pharmacovigilance Market Research Report - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Thu Mar 13, 4:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rs95v7/pharmacovigilance) has announced the addition of the "Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. A rising tide of regulatory expectations, tougher inspection regime and instant need of patient reporting has provided the much needed impetus for the growth of the pharmacovigilance market. An upsurge in number of acute and chronic diseases has consequently led to a rise in number of drug consumption, which has also elicited a growth in the number of adverse drug events and drug toxicity cases. Moreover, several high-profile safety issues, regulatory warnings, large volume of events to be reviewed along with negative media coverage have compelled the pharmaceutical players to take support of various outsourcing services. There are two major outsourcing services opted by these pharmaceutical players i.e. traditional CROs and BPOs. These outsourcing services not only provide cost savings but also helps in bringing process efficiency. Pharmaceutical companies are now forming long term partnership with the CROs and BPOs to share the costs involved in PV process right from drug discovery to post marketing approvals. In addition, PV requires skilled resources with excellent language skills and strong knowledge pertaining to case reporting. The research report on pharmacovigilance provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of pharmacovigilance market on the bases of clinical trials phases i.e. Phase I to III and post marketing surveillance (PMS). We have also mapped the trend for preference of the pharmaceutical players for in-house and outsourcing in our chapter by type of service. The global pharmacovigilance market has been segmented based on all the above mentioned parameters and market size estimates and forecasts for the period of 2011 to 2019 have been provided for each of the segments, in term of USD million, considering 2012 as the base year for calculations and 2011 representing as the historical year. The CAGR (%) of each market segment for the forecast period 2013 to 2019 has also been provided along with market size estimations. The report exclusively studies the aforementioned segments with respect to geography. Under geographic section we have covered four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (ROW). The market overview section gives a detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global pharmacovigilance market. The section also covers opportunities and market attractiveness analysis of the geographical regions. The report concludes with the competitive landscape and company profiles of major market players. These market players have been profiled on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Key Topics Covered: Introduction Executive Summary Global Pharmacovigilance Market Dynamics Global Pharmacovigilance Market, by Clinical Trial Phases Global Pharmacovigilance Market, By Type of Methods Global Pharmacovigilance Market, by Type of Service Providers Global Pharmacovigilance Market, by Geography Global Pharmacovigilance Market Share Analysis Recommendations Company Profiles List of Figures List of Tables Companies Mentioned - Accenture, Plc - Bristol-Myers Squibb - Clinquest Group B.V. - Cognizant Technology Solutions - Covance, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline (GSK) - iGATE Corporation - iMEDGlobal Corporation - inVentiv Health Inc. - ICON, Plc - Infosys - Johnson and Johnson - Novartis International AG - OptumInsight, Inc. - PRA International, Inc. - Parexel International Corporation - Pfizer, Inc. - Pharmaceutical Product Development, Inc. (PPD, Inc.) - Quantum Solutions India - Quintiles Transnational Corporation - Sanofi Aventis - Synowledge LLC - United BioSource Corporation - Wipro Limited For more information visit http://www.researchandmarkets.com/research/rs...ovigilance About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Mice Model Market 2014 - Forecasts to 2018: Inbred, Knockout & Conditioned
M2 - Wed Mar 12, 10:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lmb6vx/mice_model_market) has announced the addition of the "Mice Model Market 2014 - Forecasts to 2018: Inbred, Knockout & Conditioned" report to their offering. The global market (models and services) is valued at $1,115.2 million in 2013 and is expected to reach $1,819.9 million by 2018, growing at a CAGR of 10.3% from 2013 to 2018. Over the years, the use of mice models has increased rapidly. Mice have become the animals of choice for preclinical research in academic institutions as well as in pharmaceutical and biotechnology industries. The market has seen many innovations in the last few years, as companies have introduced new models for studying diseases like cancer and AIDS. This report categorizes the market into two broad segments, namely, mice models and services. By type, the market comprises of inbred, outbred, knockout, conditioned/surgically modified, hybrid/congenic, and spontaneous mutant mice. The inbred mice segment holds the largest share of 58% of the mice model market in 2013. This high share of inbred mice is attributed to their ability to reproduce the same results in different laboratories over a period of time. The market for mice model services is segmented into breeding, cryopreservation, quarantine, rederivation, genetic testing, model in-licensing, and other services (surgical and line rescue). The breeding services market holds the largest share of the services market and is expected to grow at the highest CAGR of 15% from 2013 to 2018, to reach $521 million by 2018. The mice care products market is categorized into cages, bedding, feed, and others. The caging market accounts for the largest share of the mice care products market, growing at a CAGR of 2.8% from 2013 to 2018 to reach $67.1 million in 2018. High investments and grants, which are leading to rising innovations in mice models, is a key factor that is likely to drive the growth of this market. In addition, the increase in the number of R&D activities in pharmaceutical industries, which are the prime users of mice models, is also responsible for driving this market. Furthermore, the high genetic similarity between mice and humans is another factor that is driving the use of mice models, globally. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Dynamics 4 Market Share Analysis, By Key Players 5 Mice Model Market Size 6 Geographic Analysis 7 Competitive Landscape 8 Company Profiles 9 Preclinical Pipeline 10 Industry Speaks 11 Cost Assessment and Mouse Model Outlicensing/Buyer Companies Assessment Companies Mentioned - Ablexis, LLC - Charles River Laboratories, Inc. - Covance, Inc. - Crescendo Biologics, - Deltagen, Inc. - Genoway Sa - Harbour Antibodies Bv - Harlan Laboratories, Inc. - Immunogenes Ag - Ingenious Targeting Laboratory - Lexicon Pharmaceuticals, Inc. - Mirimus, Inc. - Sage Labs - Taconic Farms, Inc. - The Jackson Laboratory - Transgenic, Inc. For more information visit http://www.researchandmarkets.com/research/lm...del_market
Global Life Sciences BPO Market Market Forecasts & Opportunities, 2019
M2 - Mon Mar 10, 9:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gh67xx/life_sciences_bpo) has announced the addition of the "Global Life Sciences BPO Market Market Forecasts & Opportunities, 2019" report to their offering. The life sciences BPO market comprises services offered by Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) to the biotech pharmaceutical companies. A rise in demand for low cost drugs, patent expirations and uncertain economic conditions have compelled the pharmaceutical players to take support of various outsourcing services. This support has facilitated pharma players to streamline their value chain and focus more on its core strategies. Pharmaceutical companies are now forming long term partnership with the CROs and CMOs to share the costs involved in drug discovery to post marketing approvals. Moreover, they are also leveraging CROs and CMOs expertise such as use of novel technologies, trained staff and previous experiences for effective outcomes. The research report on life sciences BPO provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of life sciences BPO on the basis of different CRO and CMO services. The CRO services comprises clinical data management, monitoring, medical writing, regulatory services, pharmacovigilance, bio-statistics, drug discovery and pre-clinical tests. The CMO services include API manufacturing, Finished Dosage Formulation development and manufacturing and Packaging. The global life sciences BPO market has been segmented based on all the above- mentioned parameters and market size estimates and forecasts for the period of 2011 to 2019 have been provided for each of the segments, in terms of USD million, considering 2012 as the base year for calculations and 2011 representing as the historical year. The market overview section gives a detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global life sciences BPO market.The section also covers opportunities, market attractiveness analysis and Porter's Five Forces analysis for the market participants. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Life Sciences BPO Market Dynamics Chapter 4 Global Life Sciences BPO Market, by Segments Chapter 5 Global Life Sciences BPO Market, by Geography Chapter 6 Global Life Sciences BPO Market Share Analysis Chapter 7 Recommendations Chapter 8 Company Profiles - Accenture, Plc - Boehringer Ingelheim GmbH - Catalent Pharma Solutions, Inc. - Charles River Laboratories International, Inc. (CRL) - Cognizant Technology Solutions - Covance, Inc. - DSM - Fareva - ICON, Plc - Infosys - International Business Machines Corporation - Lonza Group - Pharmaceutical Product Development, Inc. (PPD, Inc.) - Parexel International Corporation - Patheon, Inc. - Piramal Healthcare - PRA International, Inc. - Quintiles Transnational Corporation - Wipro Limited For more information visit http://www.researchandmarkets.com/research/gh...iences_bpo
Covance Up 18.8% Since SmarTrend Uptrend Call (CVD)
Comtex SmarTrend(R) - Fri Mar 07, 9:21AM CST
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on December 9th, 2013 at $87.45. In approximately 3 months, Covance has returned 18.78% as of today's recent price of $103.87.
Coverage on Covance Initiated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 2:20PM CST
On Mar 06, 2014, we initiated coverage on Covance.
Favorable Court Judgments, Stock Price Updates, and Upcoming Investors Conferences - Analyst Notes on Salix, Cerner, Hologic, Covance, and Synta
PR Newswire - Thu Mar 06, 8:20AM CST
Today, Analysts Review released its analysts' notes regarding Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Cerner Corporation (NASDAQ: CENR), Hologic Inc. (NASDAQ: HOLX), Covance Inc. (NYSE: CVD), and Synta Pharmaceuticals Corp. (NASDAQ: SNTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
MedAssets Beats on Q4 Earnings, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 9:45AM CST
Following the favorable earnings announcement, shares of MedAssets rose 10.8% till the last closing date
The US Clinical Research Market Outlook to 2017: Value Chain, Market Size and Segmentation by Major Therapeutic Areas
M2 - Mon Mar 03, 11:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/vt6rd9/the_us_clinical) has announced the addition of the "The US Clinical Research Market Outlook to 2017 - Led by Aging Population and Rise of Chronic Diseases" report to their offering. The report titled The US Clinical Research Market Outlook to 2017 - Led by Aging Population and Rise of Chronic Diseases' provides a comprehensive analysis of the various aspects such as market size, segmentation, trends and developments and future projections of the therapeutic areas of Oncology, Central Nervous System Disorders, Cardiovascular Diseases, Infectious Diseases and Metabolic disorders as key segments of the market. The report also provides a detailed explanation of the various macro and industry factors which are driving the growth of clinical research in the US. - The market size of The US Clinical Research Market on the basis of revenue earned by the contract research organizations in the country. - The market segmentation of The US Clinical Research Market on the basis of therapeutic areas of Oncology, Central Nervous System Disorders, Cardiovascular Diseases, Infectious Diseases and Metabolic Disorders. - The market segmentation of Oncology on the basis revenue generated in key medical conditions of Oncology which include Breast Cancer, Lung Cancer, Leukemia, Prostate Cancer, Non Small Cell Lung Cancer and other kinds of cancers. - The market size of Breast Cancer, Lung Cancer, Leukemia, Prostate Cancer, Non Small Cell Lung Cancer and other kinds of cancers on the basis of revenue generated from clinical research in these areas. - Future Outlook and Projections of Oncology and its key medical conditions. - The market size of Central Nervous System Disorders on the basis of revenue. - The market segmentation of Central Nervous System Disorders on the basis revenue generated in its key medical conditions which comprise of Strokes, Schizophrenia, Alzheimer, Multiple Sclerosis, Epilepsy and other Central Nervous System Disorders. - Future Outlook and Projections of Central Nervous System Disorders and its key medical conditions. - The market size of Cardiovascular Diseases on the basis of revenue. - The market segmentation of Cardiovascular Diseases on the basis revenue generated in its key medical conditions which comprise of Coronary Artery Disease and Heart Failures. - Future Outlook and Projections of Cardiovascular Diseases and its key medical conditions. - The market size of Infectious Diseases on the basis of revenue. - The market segmentation of Infectious Diseases on the basis revenue generated in its key medical conditions which comprise of HIV/AIDS and Hepatitis (A, B and C) - Future Outlook and Projections of Infectious Diseases and its key medical conditions. - The market size of metabolic disorders on the basis of revenue. - The market segmentation of Metabolic Disorders on the basis revenue generated in its key medical conditions which comprise of Diabetes and other metabolic disorders. - Future Outlook and Projections of Metabolic Disorders and its key medical conditions. - The market size of other therapeutic areas. - Future Outlook and Projections of other therapeutic areas. - The Future Outlook and Projections of The US Clinical Research Market on the basis of revenue. Companies Mentioned: - Albany Molecular Research inc - Charles River - Covance inc - ICON - INC Research - Inventiv Health Care - PRA International - Parexel - Pharmaceutical Product Development (PPD) - Quintiles inc For more information visit http://www.researchandmarkets.com/research/vt...s_clinical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Covance To Present At The Raymond James 35th Annual Institutional Investors Conference
PR Newswire - Mon Mar 03, 9:29AM CST
Covance Inc. (NYSE: CVD) today announced that it will present at the Raymond James 35th Annual Institutional Investors Conference on Monday, March 3, 2014 at 4:35 p.m. (ET). Investors may access a live webcast of the presentation and related slides at www.covance.com. In order to register and download any necessary software, please log on 10 minutes early.
Covance Shares Up 18.5% Since SmarTrend's Buy Recommendation (CVD)
Comtex SmarTrend(R) - Thu Feb 27, 5:02PM CST
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on December 9th, 2013 at $87.45. In approximately 3 months, Covance has returned 18.55% as of today's recent price of $103.67.
Insider Trading Alert - MXIM, CVD And NOC Traded By Insiders
at The Street - Thu Feb 27, 9:30AM CST
Stocks with insider trader activity include MXIM, CVD and NOC
Surging Rank, Surging Stock: Why BioTelemetry (BEAT) Is a Winner? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 7:38AM CST
BioTelemetry (BEAT) sees rank surges as well as price appreciation over the past few weeks, gaining over 36% in the past month.
Covance To Present At The Citi 2014 Global Healthcare Conference
PR Newswire - Mon Feb 24, 5:00PM CST
Covance Inc. (NYSE: CVD) today announced that it will present at the Citi 2014 Global Healthcare Conference on Wednesday, February 26, 2014 at 1:50 p.m. (ET). Investors may access a live webcast of the presentation and related slides at www.covance.com. In order to register and download any necessary software, please log on 10 minutes early.
Omnicare Earnings Rise but Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 11:30AM CST
For full year 2013, OCR's adjusted net earnings per share grew 9.9% to $3.43 from $3.12 a year ago, also lagging the Zacks Consensus Estimate of $3.61.
Shares of CVD Up 17.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Feb 20, 11:10AM CST
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on December 9th, 2013 at $87.45. In approximately 2 months, Covance has returned 17.72% as of today's recent price of $102.95.
Omnicare (OCR) Falls: Stock Goes Down 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 7:37AM CST
Omnicare Inc. (OCR) saw a big move last session. This stock, trading at a volatile range of $60.68–$64.54 in the past one-month time frame, showed a sharp decline yesterday at $60.98.
Why Quintiles Transnational (Q) Has A Bright Short-Term Future? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 7:30AM CST
Quintiles Transnational has seen its Zacks Rank move up from Buy to Strong Buy over the past four weeks
Why Covance (CVD) Could Be an Impressive Growth Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 7:32AM CST
Covance is well-positioned for future earnings growth and could be a strong growth stock contender
Quintiles Transnational Holdings (Q) Jumps: Stock Rises 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 7:57AM CST
Quintiles Transnational Holdings Inc. (Q) was a big mover last session, as the company saw its shares rise over 5% on the day.
(0)
(0)Covance Inc. (CVD) Stock Research Links
Scroll down for more posts ▼